In AD, tau aggregation and spreading appears to be enabled by amyloid‐beta aggregation, but therapeutics aimed at regulating the amyloid cascade have failed to prevent disease progression in symptomatic patients (Giacobini & Gold, 2013; Holtzman et al., 2016). Here, MAPT is linked to Alzheimer disease.